• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向人类癌症患者特定染色质复合物的治疗指数。

Therapeutic index of targeting select chromatin complexes in human cancer patients.

机构信息

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA. Electronic address: https://twitter.com/@yuangao_yg.

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.

出版信息

Curr Opin Genet Dev. 2024 Apr;85:102162. doi: 10.1016/j.gde.2024.102162. Epub 2024 Feb 24.

DOI:10.1016/j.gde.2024.102162
PMID:38401489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11072572/
Abstract

Aberrant chromatin regulation can promote the initiation and progression of human cancer. An improved understanding of such mechanisms has resulted in the identification of cancers with an enhanced dependency on specific chromatin regulatory proteins relative to nonmalignant cell types. Hence, targeting of such complexes with small molecules has significant therapeutic potential in oncology. In recent years, several drugs have been developed and evaluated in human cancer patients, which can influence tumor biology by reprogramming of chromatin structure. In this review, we summarize several of the known mechanisms that endow cancer cells with a powerful dependency on chromatin regulation that exceeds the requirements for normal tissue homeostasis. We also summarize the remarkable small-molecule inhibitors that exploit chromatin regulator dependencies with a clear therapeutic benefit in human cancer patients.

摘要

异常的染色质调控可以促进人类癌症的发生和发展。对这些机制的深入了解已经确定了一些癌症,相对于非恶性细胞类型,这些癌症对特定的染色质调控蛋白具有更高的依赖性。因此,用小分子靶向这些复合物在肿瘤学中有很大的治疗潜力。近年来,已经开发并评估了几种药物用于人类癌症患者,这些药物可以通过重编程染色质结构来影响肿瘤生物学。在这篇综述中,我们总结了几种已知的机制,这些机制赋予了癌细胞对染色质调控的强大依赖性,超过了正常组织内稳态的要求。我们还总结了利用染色质调节因子依赖性的显著小分子抑制剂,这些抑制剂在人类癌症患者中有明确的治疗益处。

相似文献

1
Therapeutic index of targeting select chromatin complexes in human cancer patients.靶向人类癌症患者特定染色质复合物的治疗指数。
Curr Opin Genet Dev. 2024 Apr;85:102162. doi: 10.1016/j.gde.2024.102162. Epub 2024 Feb 24.
2
Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies.哺乳动物 SWI/SNF 染色质重塑复合物:新兴机制和治疗策略。
Trends Genet. 2020 Dec;36(12):936-950. doi: 10.1016/j.tig.2020.07.011. Epub 2020 Aug 29.
3
Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy.靶向癌细胞中的染色质重塑因子:癌症治疗中的有前途的分子。
Int J Mol Sci. 2022 Oct 24;23(21):12815. doi: 10.3390/ijms232112815.
4
The Roles of Chromatin Remodeling Proteins in Cancer.染色质重塑蛋白在癌症中的作用。
Curr Protein Pept Sci. 2016;17(5):446-54. doi: 10.2174/1389203717666160122120713.
5
Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors.靶向治疗 BET 溴结构域和其他包含表观遗传乙酰化识别结构域的因子。
Curr Opin Genet Dev. 2024 Jun;86:102181. doi: 10.1016/j.gde.2024.102181. Epub 2024 Apr 2.
6
Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy.利用 SWI/SNF 染色质重塑复合物的漏洞进行癌症治疗。
Oncogene. 2021 May;40(21):3637-3654. doi: 10.1038/s41388-021-01781-x. Epub 2021 May 3.
7
Chromatin dependencies in cancer and inflammation.染色质在癌症和炎症中的依赖性。
Nat Rev Mol Cell Biol. 2018 Apr;19(4):245-261. doi: 10.1038/nrm.2017.113. Epub 2017 Nov 29.
8
Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.人类癌症中 SWI/SNF 染色质重塑基因的失活突变。
Jpn J Clin Oncol. 2013 Sep;43(9):849-55. doi: 10.1093/jjco/hyt101. Epub 2013 Jul 30.
9
Editorial (Thematic Issue: Chromatin Structure Regulating Proteins: Biology and Therapeutic Potential for Cancer).社论(专题:染色质结构调控蛋白:生物学特性与癌症治疗潜力)
Curr Protein Pept Sci. 2016;17(5):400. doi: 10.2174/1389203717999160122121454.
10
Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer.靶向染色质调节蛋白的小分子抑制剂用于癌症治疗
Curr Protein Pept Sci. 2016;17(5):455-62. doi: 10.2174/1389203717666160122121340.

引用本文的文献

1
Editorial overview: Breaking boundaries: new frontiers in chromatin regulation for cancer therapy.社论综述:突破界限:癌症治疗中染色质调控的新前沿
Curr Opin Genet Dev. 2024 Oct;88:102255. doi: 10.1016/j.gde.2024.102255. Epub 2024 Sep 3.

本文引用的文献

1
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.Menin 抑制剂 revumenib 在伴有 KMT2A 重排或 NPM1 突变的白血病中的应用。
Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15.
2
MEN1 mutations mediate clinical resistance to menin inhibition.MEN1 突变介导了对 menin 抑制的临床耐药性。
Nature. 2023 Mar;615(7954):913-919. doi: 10.1038/s41586-023-05755-9. Epub 2023 Mar 15.
3
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.阿替利珠单抗与他泽司他联合治疗复发/难治性弥漫性大B细胞淋巴瘤患者:Ib期研究结果
Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):504-512. doi: 10.1016/j.clml.2021.12.014. Epub 2021 Dec 24.
4
Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.全基因组 CRISPR 筛选揭示 CREBBP 和 EP300 之间在弥漫性大 B 细胞淋巴瘤中的合成致死相互作用。
Cell Death Dis. 2021 Apr 28;12(5):419. doi: 10.1038/s41419-021-03695-8.
5
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.Tazemetostat 治疗 INI1/SMARCB1 缺失的晚期上皮样肉瘤:一项国际、开放标签、2 期篮子研究。
Lancet Oncol. 2020 Nov;21(11):1423-1432. doi: 10.1016/S1470-2045(20)30451-4. Epub 2020 Oct 6.
6
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.塔西美替尼治疗复发或难治性滤泡性淋巴瘤患者的疗效:一项开放标签、单臂、多中心、2 期临床试验。
Lancet Oncol. 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. Epub 2020 Oct 6.
7
Therapeutic targeting of preleukemia cells in a mouse model of mutant acute myeloid leukemia.在一个突变型急性髓系白血病的小鼠模型中对白血病前细胞进行治疗性靶向。
Science. 2020 Jan 31;367(6477):586-590. doi: 10.1126/science.aax5863.
8
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.Menin 抑制剂 MI-3454 诱导 MLL1 重排和 NPM1 突变的白血病模型缓解。
J Clin Invest. 2020 Feb 3;130(2):981-997. doi: 10.1172/JCI129126.
9
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.一种 Menin-MLL 抑制剂可诱导特定的染色质变化,并消除 MLL 重排白血病模型中的疾病。
Cancer Cell. 2019 Dec 9;36(6):660-673.e11. doi: 10.1016/j.ccell.2019.11.001.
10
A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells .CRISPR 干扰 CBP 和 p300 选择性诱导膀胱癌细胞合成致死性。
Int J Biol Sci. 2019 May 11;15(6):1276-1286. doi: 10.7150/ijbs.32332. eCollection 2019.